Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Cash and Equivalents of $28.65 million for fiscal year 2025.
HERON THERAPEUTICS, INC. /DE/ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $28.65M | +11.0% |
| 2024 | $25.80M | -10.0% |
| 2023 | $28.68M | +86.7% |
| 2022 | $15.36M | -83.0% |
| 2021 | $90.54M | -13.9% |
| 2020 | $105.14M | +46.2% |
| 2019 | $71.90M | +125.8% |
| 2018 | $31.84M | -78.0% |
| 2017 | $144.58M | +977.9% |
| 2016 | $13.41M | -82.2% |
| 2015 | $75.18M | +3.4% |
| 2014 | $72.67M | +0.5% |
| 2013 | $72.29M | +35.1% |
| 2012 | $53.51M | +197.7% |
| 2011 | $17.97M | +752.3% |
| 2010 | $2.11M | -72.2% |
| 2009 | $7.59M | -23.8% |
| 2008 | $9.97M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.07M | +67.3% | +160.8% |
| June 30, 2025 | $16.52M | -10.2% | -14.3% |
| March 31, 2025 | $19.27M | -5.8% | -25.3% |
| December 31, 2024 | $25.80M | -10.0% | +0.2% |
| September 30, 2024 | $25.74M | -26.2% | +40.0% |
| June 30, 2024 | $18.39M | +36.6% | -10.1% |
| March 31, 2024 | $20.45M | -24.5% | -28.7% |
| December 31, 2023 | $28.68M | +86.7% | -17.7% |
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +11.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, HERON THERAPEUTICS, INC. /DE/’s cash and equivalents has grown by 187.4% (from $9.97 million to $28.65 million).
- The most recent figure is from HERON THERAPEUTICS, INC. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: